Company intelligence / Profile preview

Schering Nordiska

Solna, Sweden

Ownership: Private
Development stage: Other

Overview

Schering Nordiska was the Nordic subsidiary of the German pharmaceutical company Schering AG, specializing in specialized healthcare sectors such as gynecology, neurology, and diagnostic imaging. Based in Stockholm, Sweden, the company was responsible for the marketing and distribution of key products including Betaferon for multiple sclerosis and various hormonal contraceptives. Following the acquisition of Schering AG by Bayer in 2006, Schering Nordiska's operations were integrated into Bayer AB. The company played a vital role in the Nordic pharmaceutical market, providing innovative treatments and diagnostic tools to healthcare providers across Sweden, Norway, Denmark, Finland, and Iceland.

Therapeutic areas: Women's HealthOtherNeurologyOncology
Modalities: Small moleculeBiologicRecombinant proteinHormone
Industry: Biotech

Beyond the preview

Go deeper on Schering Nordiska.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schering Nordiska.

Explore the full profile